Oxidative stress and endothelin-1 in atherosclerotic renal artery stenosis and effects of renal angioplasty

Kidney and Blood Pressure Research

Volumn 34, Issue 6, 2011, Pages 396-403

  Saeed, Aso ^a   Herlitz, H ^a   Nowakowska Fortuna, E ^a   Nilsson, U ^a   Alhadad, A ^b   Jensen, G ^a   Mattiasson, I ^b   Lindblad, B ^b   Gottsater A ^b   Guron, G ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Endothelin 1; Oxidative stress; Renal angioplasty; Renal artery stenosis; Renovascular hypertension

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ALBUMIN; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; KIDNEY ANGIOGRAPHY; KIDNEY ARTERY STENOSIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION;

AGED; ANGIOPLASTY; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL ARTERY OBSTRUCTION; URIC ACID;

EID: 79958765639     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000328732     Document Type: Article

References (35)

1. Mailloux LU, Napolitano B, Bellucci AG, Vernace M, Wilkes BM, Mossey RT: Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: A 20-year clinical experience. Am J Kidney Dis 1994; 24: 622-629.
2. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P: Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J Hypertens 1999; 17: 1743-1750.
3. Conlon PJ, Little MA, Pieper K, Mark DB: Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int 2001; 60: 1490-1497.
4. The AI, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, Baigent C, Carr S, Chalmers N, Eadington D, Hamilton G, Lipkin G, Nicholson A, Scoble J: Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 2009; 361: 1953-1962.
5. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF: Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET A -receptor antagonist. Circulation 1997; 96: 1593-1597.
6. Weiss D, Kools JJ, Taylor WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in APOE-deficient mice. Circulation 2001; 103: 448-454.
7. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG: Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97: 1916-1923.
8. Lerman LO, Nath KA, Rodriguez-Porcel M, Krier JD, Schwartz RS, Napoli C, Romero JC: Increased oxidative stress in experimental renovascular hypertension. Hypertension 2001; 37: 541-546.
9. Guron GS, Grimberg ES, Basu S, Herlitz H: Acute effects of the superoxide dismutase mimetic tempol on split kidney function in two-kidney one-clip hypertensive rats. J Hypertens 2006; 24: 387-394.
10. Welch WJ, Mendonca M, Aslam S, Wilcox CS: Roles of oxidative stress and AT1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension 2003; 41: 692-696.
11. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K: Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002; 346: 1954-1962.
12. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, Seta F, Capone ML, Tacconelli S, Palatresi S, Bencini C, Del Vecchio C, Mansueto G, Arosio E, Santonastaso CL, Lechi A, Morganti A, Patrono C: Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002; 106: 2800-2805.
13. Parildar M, Parildar Z, Oran I, Kabaroglu C, Memis A, Bayindir O: Nitric oxide and oxidative stress in atherosclerotic renovascular hypertension: Effect of endovascular treatment. J Vasc Interv Radiol 2003; 14: 887-892.
14. Ballew JR, Fink GD: Role of ET A receptors in experimental Ang II-induced hypertension in rats. Am J Physiol Regul Integr Comp Physiol 2001; 281:R150-R154.
15. Wilhelmsen L, Johansson S, Rosengren A, Wallin I, Dotevall A, Lappas G: Risk factors for cardiovascular disease during the period 1985-1995 in Göteborg, Sweden. The GOTMONICA project. J Intern Med 1997; 242: 199-211.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology C: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
17. Ahotupa M, Ruutu M, Mantyla E: Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem 1996; 29: 139-144.
18. Rice-Evans C, Miller NJ: Total antioxidant status in plasma and body fluids. Methods Enzymol 1994; 234: 279-293.
19. Reznick AZ, Packer L: Oxidative damage to proteins: Spectrophotometric method for carbonyl assay. Methods Enzymol 1994; 233: 357-363.
20. Alhadad A, Guron G, Fortuna-Nowakowska E, Saeed A, Mattiasson I, Jensen G, Lindblad B, Gottsater A, Herlitz H: Renal angioplasty causes a rapid transient increase in inflammatory biomarkers, but reduced levels of interleukin- 6 and endothelin-1 one month after intervention. J Hypertens 2007; 25: 1907-1914.
21. Ceylan A, Karasu C, Aktan F, Guven C, Can B, Ozansoy G: Effects of simvastatin treatment on oxidant/antioxidant state and ultrastructure of diabetic rat myocardium. Gen Physiol Biophys 2003; 22: 535-547.
22. Cangemi R, Loffredo L, Carnevale R, Perri L, Patrizi MP, Sanguigni V, Pignatelli P, Violi F: Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: Effect on circulating vitamin E. Eur Heart J 2008; 29: 54-62.
23. Yilmaz MI, Baykal Y, Kilic M, Sonmez A, Bulucu F, Aydin A, Sayal A, Kocar IH: Effects of statins on oxidative stress. Biol Trace Elem Res 2004; 98: 119-127.
24. Wu R, Lamontagne D, de Champlain J: Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002; 105: 387-392.
25. Roberts LJ, Morrow JD: Measurement of F 2 - isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-513.
26. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, Sato Y, Nagao K, Kanmatsuse K, Kushiro T, Surugadai Atherosclerosis Regression Investigators: Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 2005; 96: 1089-1094.
27. Demirbag R, Yilmaz R, Kunt AS, Gur M, Ulucay A, Unlu D: Relationship between plasma total antioxidant capacity and thoracic aortic intima-media thickness. Echocardiography 2006; 23: 183-188.
28. Reinisch N, Kiechl S, Mayr C, Schratzberger P, Dunzendorfer S, Kahler CM, Buratti T, Willeit J, Wiedermann CJ: Association of high plasma antioxidant capacity with new lesion formation in carotid atherosclerosis: A prospective study. Eur J Clin Invest 1998; 28: 787-792.
29. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-1193.
30. Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, Medina F, Tajer C, Doval H, Badaracco R: Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: Results of a randomized, double-blind, placebo- controlled study. Am Heart J 2005; 149: 451-457.
31. Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F: Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 2006; 17: 1466-1471.
32. Chao HH, Liu JC, Lin JW, Chen CH, Wu CH, Cheng TH: Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin 2008; 29: 1301-1312.
33. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez- Iturbe B, Herrera-Acosta J, Mazzali M: Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003; 41: 1183-1190.
34. Osswald H, Schmitz HJ, Kemper R: Tissue content of adenosine, inosine and hypoxanthine in the rat kidney after ischemia and postischemic recirculation. Pflügers Arch 1977; 371: 45-49.
35. Miller WL, Thomas RA, Berne RM, Rubio R: Adenosine production in the ischemic kidney. Circ Res 1978; 43: 390-397.